Actively Recruiting
Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
Led by Sun Yat-sen University · Updated on 2026-02-05
25
Participants Needed
1
Research Sites
162 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Through the combination of aparolitovorelli monoclonal antibody and lenvatinib neoadjuvant therapy, partial nephrectomy can be successfully and safely performed in patients with localized renal cell carcinoma (T1N0M0 or T2N0M0) who have indications for kidney preservation surgery but have difficulty in preserving the kidney (R.E.N.A.L. score \>= 10).
CONDITIONS
Official Title
Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent form
- Age between 18 and under 80 years
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- Expected survival of at least 3 months
- Biopsy-confirmed renal clear cell carcinoma or predominantly clear cell carcinoma
- Willingness to undergo kidney preservation surgery
- Indications for kidney preservation surgery with high difficulty (stage T1N0M0 or T2N0M0, R.E.N.A.L. score 6 10)
- At least one measurable lesion suitable for repeated accurate measurements
- Good organ function meeting specific laboratory criteria for blood counts, liver function, and coagulation
- Willing and able to comply with study schedules and requirements
You will not qualify if you...
- Presence of lymph node metastasis
- Tumor surrounding the renal artery
- Renal vein cancer thrombus
- Diffuse tumor growth without clear boundary from normal kidney tissue
- Poor general condition or inability to tolerate general anesthesia
- Serious cardiovascular or cerebrovascular diseases, uncontrolled hypertension or diabetes
- Long-term use of immunosuppressants after organ transplantation
- Current use of immunosuppressive drugs
- Active infection or fever
- Diagnosis of T-cell lymphoma or myeloma
- Concurrent malignant tumors or recent history of other malignant tumors within six months
- Metastatic renal cell carcinoma
- Recent use of Chinese herbal medicine or immunomodulatory drugs with anti-tumor effects within 14 days
- Prior systemic treatments like thymosin, interferon, or interleukin (except local treatments for pleural effusion)
- Active or potentially recurrent autoimmune diseases except certain stable conditions
- Participation in another interventional clinical study
- History of mental illness, drug abuse, or alcoholism
- Pregnant or breastfeeding women
- Any condition or abnormality that could interfere with study results or participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sun Yat-sen University Cancer Center
Guangzhou, China, 0755
Actively Recruiting
Research Team
Z
Zhiling Zhang, M.D
CONTACT
Y
Yulu Peng, M.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here